// App-Quantinova.ai

OP0194 (2022) : COMBINATION ANAKINRA AND TOCILIZUMAB TO TREAT REFRACTORY MACROPHAGE ACTIVATION SYNDROME TRIGGERED BY ADULT-ONSET STILL’S DISEASE.

Researchers

Presenter

  • E. Alveyn

Principal Investigators

  • A. Rutherford

Medical Centers

  • King’s College London Centre for Rheumatic Diseases, Department of Inflammation Biology, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Macrophage activation syndrome

  • Adult onset Still's disease

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

  • Anakinra

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved